Lantern Pharma (LTRN) Cash from Operations (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Cash from Operations came in at 3772627.0 in Q1 2026, up 13.78% YoY from 3315704.74 in Q1 2025, and down 35.12% on a QoQ basis from 2792113.0 in Q4 2025.
Lantern Pharma (LTRN) Cash from Operations (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Cash from Operations data on file, last reported at 3772627.0 in Q1 2026.
- Quarterly Cash from Operations rose 13.78% year-over-year to 3772627.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15073997.0 (up 21.16% YoY) and the FY2025 annual result came in at 15676980.0, up 11.99% from the prior year.
- Cash from Operations fell to 3772627.0 in Q1 2026, from 2792113.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2668863.0 in Q4 2022 to a low of 5582253.0 in Q3 2024.
- A 5-year average of 3786873.41 and a median of 3757156.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 58.37% — and 2025, when it advanced 29.7%.
- Tracing LTRN's Cash from Operations over 5 years: stood at 2668863.0 in 2022, then fell by 26.85% to 3385350.0 in 2023, then retreated by 17.32% to 3971787.0 in 2024, then increased by 29.7% to 2792113.0 in 2025, then sank by 35.12% to 3772627.0 in 2026.
- The last three Cash from Operations figures came in at 3772627.0 (Q1 2026), 2792113.0 (Q4 2025), and 4571980.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | -3.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.77 Mn |
| Mar 31, 2026 | -3.77 Mn |
| Dec 31, 2025 | -2.79 Mn |
| Dec 31, 2025 | -2.79 Mn |
| Sep 30, 2025 | -4.57 Mn |
| Sep 30, 2025 | -4.57 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Mar 31, 2025 | -4.38 Mn |
| Mar 31, 2025 | -4.38 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | -5.58 Mn |
| Sep 30, 2024 | -5.58 Mn |
| Jun 30, 2024 | -5.19 Mn |
| Jun 30, 2024 | -5.19 Mn |
| Mar 31, 2024 | -3.07 Mn |
| Mar 31, 2024 | -3.07 Mn |
| Dec 31, 2023 | -3.39 Mn |
| Dec 31, 2023 | -3.39 Mn |